* Announced new results from its ongoing phase 1/2
GBT440-001 study in sickle cell disease

The post BRIEF-Global Blood Therapeutics says phase 1/2 data supports hypothesis that GBT440 inhibits sickle hemoglobin appeared first on NASDAQ.